Skip to Content
Find More Like This
Return to Search

TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY

United States Patent Application

20090274626
A1
View the Complete Application at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.
Kenny, Paraic A. (Templemore, IE), Bissell, Mina J. (Berkeley, CA)
The Regents of the University of California (Oakland CA)
12/ 022,049
January 29, 2008
STATEMENT OF GOVERNMENT SUPPORT [0002] This invention was made with government support by Contract No. DE-AC02-05CH11231 awarded by the US Department of Energy, Office of Biological and Environmental Research, and an Innovator Award BC012005 and Contract No. DOD BCRP DAMD17-00-1-0224 awarded by the Department of Defense Breast Cancer Research Program. The government has certain rights in this invention.